One day, we won't need to call it "women's health"
A decade ago, "green chemistry" was a hard sell — now it's just how chemistry gets done. Drawing on that shift, here's why women's health is on the same trajectory, and what regulation, funding data, and momentum tell us about how fast it could get there. Reflection from our attendance to Women’s Health Horizons conference in London.
The next strategic frontiers of medtech
Where should medtech and femtech companies focus their international expansion efforts after establishing EU and US market presence? This article analyses eight high-potential markets across four global regions — Anglosphere, East Asia, MENA, and Latin America — ranked against three strategic criteria: ROI and medtech infrastructure, femtech readiness, and regulatory alignment with international harmonisation frameworks including MDSAP and CE Mark mutual recognition agreements. Whether you are mapping your next regulatory strategy or building a market entry roadmap, this evidence-based analysis offers a practical starting point — with an honest look at what the data says and where gut instinct still has a role to play.
At Women’s Health Week Europe
The go-to regulatory compliance agency for femtech. Find out more.